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1. Introduction 
Although recurrent unprovoked seizures or epilepsy has been known for more than three 
thousand years, and even considering pivotal contributions like that of Hypocrates (circa 
400 BC) establishing epilepsy as a brain disease instead of a religious or evil phenomenon, 
it was not until the 20th century that the first relatively effective antiepileptic drugs were 
discovered. Starting from phenobarbital and phenytoin almost 100 years ago, much 
research has been devoted to the development of new, more active drugs to treat such a 
broad category of symptom complexes (Krasowski, 2010). A chronological overview of the 
aforementioned development would provide interesting information about trial and 
errors in antiepileptic therapy, but from a chemical point of view (drug discovery) a 
classification according to structure is by far more useful. That is the aim of this review, 
thus covering the most relevant literature concerning synthetic approaches to the main 
anticonvulsant drugs. More detailed, comprehensive reviews on some of the main anti-
epileptic drugs (AEDs) have been reported so far (Carril et al., 2007; Kraus et al., 2010), in 
some cases describing also aspects like pharmacokinetics, medicinal uses, approval for 
commercialization, etc. The present review intends to give a concise outlook at the most 
significant strategies employed in the synthesis of a good number of AEDs. Currently 
marketed drugs and some others in development will be briefly examined. Finally, a 
slightly more profound coverage has been given to some sections (i.e. carbamazepine, 
oxcarbazepine and eslicarbazepine acetate) on the basis of the relevance, therapeutic 
importance or promising applications of some AEDs over other ones occasionally 
employed or with a narrower application spectrum. 
2. Results 
2.1 First generation AEDs and related 
2.1.1 Carbamazepine, oxcarbazepine and eslicarbazepine acetate 
Despite the obvious similarity between these three compounds, which share a N-
carbamoyldibenzo[b,f]azepine framework, their chronological appearance as antiepileptic 
drugs has been delayed for more than 30 years. Indeed, carbamazepine was first marketed 
as a drug to treat trigeminal neuralgia in 1962 and then started to be used as an 
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anticonvulsant in the UK in 1965 and approved in the US by 1967 (Schlinder, 1958). 
Oxcarbazepine was first synthesized in 1965, just a few years after its precursor 
carbamazepine, but it was not until 1990 that it was approved to treat epileptic seizures in 
Denmark, the rest of the EU (1999) and US (2000). Geigy (now part of Novartis) was the 
company that discovered both carbamazepine and oxcarbazepine drugs and 
commercialized them under the trade names of Tegretol® and Trileptal® respectively. The 
last member of this family, eslicarbazepine acetate, which has been developed by Bial, has 
been approved in Europe as an adjunctive therapy for adults with refractory partial-onset 
seizures and is in review for US approval (Chung, 2010). 
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Scheme 1. Summary of metabolic paths concerning carbamazepine, oxcarbazepine and 
eslicarbazepine acetate. 
Scheme 1 shows a summary of the metabolic paths and connections between these drugs. 
Both oxcarbazepine and eslicarbazepine acetate are considered prodrugs of 
eslicarbazepine or S-licarbazepine, the most active and selective (towards preferential 
modulation of inactivated voltage-dependent sodium channels more than sodium 
channels in the resting state) metabolite. The also active (and toxic) carbamazepine-10,11-
epoxide is generated by metabolic oxidation of carbamazepine, but this compound and 
the R-isomer of licarbazepine (R-licarbazepine, generated in a approximate 5% proportion 
from eslicarbazepine acetate and 25% from oxcarbazepine) result to be less active and 
selective. Finally, trans-10,11-dihydroxy-10,11-dihydrocarbamazepine is an inactive 
metabolite which is excreted in the urine mainly in an unconjugated form. One of the 
advantages of oxcarbazepine over carbamazepine is a clear reduction of the impact on the 
liver and prevention of the serious forms of anemia or agranulocytosis occasionally 
associated with carbamazepine. A tolerability improvement has been also observed when 
comparing oxacarbazepine with the third generation drug eslicarbazepine acetate. (Kraus 
et al., 2010). 
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Scheme 2. A first selection of the reported approaches to carbamazepine and oxcarbazepine. 
Both carbamazepine and oxcarbazepine have been crucial milestones, reference drugs in 
the therapy of epilepsy for a long time, and eslicarbazepine acetate looks like a suitable 
candidate for the future. Due to the aforementioned importance of carbamazepine and 
oxcarbazepine, a good number of synthetic strategies have been developed for the access 
to both dibenzoazepine drugs. Moreover, most of the existing methodologies share 
common substrates and intermediates in such a way that it can be said they are 
interconnected, as shown in schemes 2 and 3, and many alternative protocols have been 
developed for the same step or transformation. In fact, some of the publications or patents 
claim overall yield improvements by slight modifications in the procedures for just one or 
two steps of the whole sequence. One of those common intermediates is 10,11-dihydro-
5H-dibenzo[b,f]azepine, also known as iminodibenzyl, obtained by an initial oxidative 
coupling of o-nitrotoluene, reduction of the nitro groups and PPA-promoted cyclization 
(Method A). After oxidation to dibenzoazepine ring, a carbamoylation step (see 
alternative procedures for this transformation) renders carbamazepine (Aufderhaar et al., 
1980). A relatively straightforward approach to oxcarbazepine from iminodibenzyl 
involves benzylic direct or stepwise (Method B) oxidation after a suitable N-
functionalization (carbamoylation, cyanation, etc.). Another well-established strategy 
relies on the preparation of 10-methoxy or 10-haloiminostilbene derivatives by a N-
protection/halogenation/elimination sequence (Karusala et al., 2009) or alternatively by a 
dehydrohalogenation of a halomethoxy intermediate obtained by using 1,3-
dihalodimethylhydantoin (Method C). Demethylation or hydrolysis and carbamoylation 
steps provide target oxcarbazepine (Gupta et al., 2007). 
Scheme 3 displays another set of synthetic strategies towards oxcarbazepine. 
Carbamazepine, though a final product itself, has been employed as intermediate for the 
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synthesis of oxcarbazepine. Epoxidation of the former and rearrangement by iodide salts or 
hydrogenation/oxidation (Method D) provided target compound (Heckendorn et al., 1982). 
Other interesting approaches from iminostilbene involved the use of 10-nitro derivative 
intermediates and, in some cases, of the corresponding oximes. Iron-catalyzed reduction 
and acidic hydrolysis (Methods E and F) were the key steps in these synthetic sequences 
(Aufderhaar, 1981; Eidenhammer et al., 2000). The latter approaches are related to the 
originally employed industrial procedure at Novartis (Fuenfschilling et al., 2005). 
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Scheme 3. Other synthetic sequences leading to carbamazepine and oxcarbazepine. 
In the last years more innovative entries to oxcarbazepine have been reported. As shown in 
Scheme 4, an intramolecular Friedel-Crafts acylation performed at a 2-
carboxymethyldiarylamine intermediate provides 10-methoxyiminostilbene, which upon 
carbamoylation and hydrolysis (Method G) provides target compound (Kaufmann et al., 
2004). A tandem remote metalation/cyclization was applied to 2-carboxamido-2’-
methyldiarylamines (Method H), thus affording the corresponding dibenzoazepinones 
which were finally N-deprotected and carbamoylated, or alternatively transformed into the 
aforementioned 10-methoxyiminostilbene and carbamoylated/hydrolysed (Lohse et al., 
2001). A straightforward, efficient approach to oxcarbazepine, based two palladium-
catalyzed N-arylation reactions, was recently reported (Scheme 5). The scope of the latter 
strategy was expanded by the synthesis of a series of analogs which incorporated different 
substituents in the arene or heteroarene rings (Carril eta al., 2005, 2007). 
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Scheme 4. Remote metalation/cyclization and intramolecular F-C acylation as key steps for 
the synthesis of oxcarbazepine. 
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Scheme 5. Palladium-catalyzed sequential N-arylations for the synthesis of oxcarbazepine 
and several structural analogs. 
Considering the above metabolic paths and the commercial availability of oxcarbazepine, all 
the synthetic approaches to eslicarbazepine acetate start from the former AED, as displayed 
in Scheme 6. A chiral resolution of the reduction products of oxcarbazepine under standard 
conditions, the racemic mixture of 10-hydroxyderivatives, can be performed by means of 
either menthoxyacetic acid chloride or L-(+)-tartaric acid acetic anhydride (Method I). 
Eslicarbazepine would be obtained in this way and then transformed into eslicarbazepine 
acetate by acetylation (Benes et al., 1999; Learmonth, 2002). A more efficient approach to 
eslicarbazepine implies an stereoselective reduction of oxcarbazepine (Method J) using 
formic acid derivatives and a chiral ruthenium catalyst with p-cymene and sulfonamide 
(S,S)-TsDAEN ligands (Learmonth et al., 2007). Finally, an asymmetric catalytic 
hydrogenation catalyzed by Rh((SSRR)-TangPhos)(COD)BF4 complex also afforded highly 
enantiopure eslicarbazepine acetate (Method K), this time from achiral 10-
acetoxyiminostilbene, readily prepared from oxcarbazepine (Yu et al., 2007). 
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Scheme 6. Synthesis of eslicarbazepine acetate from oxcarbazepine. 
2.1.2 Phenobarbital, primidone, phenytoin and phosphenytoin 
Phenobarbital (PHB, Luminal®) is one of the first discovered AEDs and still remains as 
effective as more modern drugs in a wide variety of seizures (Kwan & Brodie, 2004). PHB 
acts directly on GABAA receptors by modulating chloride currents through receptor 
channels, as well as inhibits glutamate induced depolarizations. Similar mechanism of 
action is shared by primidone (Mysoline®), another AED related to the barbiturates, which is 
partly metabolized to PHB in the body (Gallagher et al., 1972). Currently they use is limited 
because of their adverse effects but in developing countries, PHB is still widely employed 
for the treatment of all types of seizures except absence due to its low cost. 
Since its early discovery and introduction in 1938, phenytoin (PHT, 5,5-diphenylhydantoin, 
Dilantin®) has become one of the most commonly used drug in adjunctive treatments for 
partial and generalized seizures as well as various epileptic syndromes (Tunnicliff, 1997). 
The primary site of action appears to be the motor cortex where, by blocking voltage-
sensitive sodium channels in neurons, the spread of seizures is reduced and the 
development of maximal seizure activity is limited. PHT is a highly effective and 
economical AED but the complications in its administration associated to its 
physicochemical properties led to the development of a better tolerated and safer derivative, 
fosphenytoin (Cerebyx®), a phosphate ester containing PHT prodrug (Luer, 1998). 
Despite their differences, the chemical structure of these four derivatives is related. Among 
the variety of approaches reported in literature for their synthesis (Roth & Kleeman, 1988), 
there are two general and common methods for the preparation of the heterocyclic cores 
(Scheme 1): the condensation of dicarbonyl derivates with urea under basic conditions 
(method A) and the treatment of β-diamido/β-aminoamido compounds with phosgene 
(method B). Several related approaches have been developed in which alternative reagents 
to urea and phosgene are employed, such as guanidine (method C) and thiourea (method 
D), or formic acid (method E), respectively. In addition to these methods, modifications on 
the heterocyclic ring include the phenyl insertion, both under superacidic conditions 
(method F) (Klummp et al., 1998) and/or by using phenyllead(IV) compounds (method G) 
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Scheme 7. General methods for the synthesis of phenobarbital, primidone, phenytoin and 
fosphenytoin. 
(Pinhey & Rowe, 1980), and oxidation reactions (method H) (Mac Leod et al., 2008). Most of 
these classical methods suffer from general drawbacks, including long reaction times, low 
yield, and difficult operating conditions. However, by the application of new technologies 
or the use of newly developed heterogeneous reagents, their scope has been considerably 
extended. Thus, for example, the synthesis of PHT in almost quantitatively yield is 
accomplished using method A assisted by microwave irradiation (Safari et al., 2009). 
Finally, fosphenytoin is readily available from PHT by its sequential treatment with 
formaldehyde and, after activation of the so-obtained aminoalcohol, with the corresponding 
phosphoric acid. The recently reported use of an in situ prepared tertiary ammonium 
phosphate as phosphorylating reagent has resulted in a considerably improvement 
regarding reaction yield and steps, affording fosphenytoin in an overall 82% yield (Grassi & 
Volante, 2005). 
2.1.3 Valproate and valproic acid 
Valproic acid (VPA, Depakote®, Depakene®) and sodium valproate (Depacon®, Epilim®), are 
a broad spectrum AEDs very effective for generalized seizure types. With an unknown 
mechanism of action, VPA has the shortest half life (10-15 h) among the all existing AEDs 
(Badir et al., 1991), which results on a multiple daily dosing administration. Although 
clinically effective, its use is restricted because of rare but potentially severe life threatening 
side effects, such as teratogenicity and hepatotoxicity. 
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Scheme 8. General methods for the synthesis of valproic acid. 
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The alkylation of carboxy acid derivatives with n-propyl halides is the most general 
approach reported in literature for the synthesis of VPA and so far the most effective 
(Santaniello et al., 1998). Starting from diverse substrates, different variations of the method 
have been carried out, as the elimination-hydrolysis of 2,2-dipropyl acetoacetic ethyl ester 
via retroclaisen reaction promoted by NaOH (method B) or the monoalkylation of a soluble 
metalated magnesium carboxylate derived from valeric acid (method C). Among all, the 
classical alkylation β-activated carboxylic esters (method A) is still the better studied 
method. The optimization of the hydrolysis and decarboxylation steps had provided a one-
pot, easy to operate and high yielding (84%) synthesis of VPA using methanesulfonic acid 
(Zeiler, 1994). Alternatively, the transformation of 4-heptanone into VPA has also received 
much attention. Recently, a novel approach has been described in which after addition of 2-
chloroacetonitrile, the hydrolysis of the so-obtained epoxynitrile is successfully 
accomplished in presence of a phase transfer catalyst (method D), yielding VPA in an 
overall 71% (Nagarajan et al., 2009). 
2.2 Second generation AEDs 
2.2.1 Clorazepate and clonazepam 
Benzodiazepines (BDZs) are a class of drugs that have long been employed to treat 
convulsive seizures as well as used as tranquilizers, sedatives and muscle relaxants (Ashton, 
1994). Clonacepam (Klonopin®) was the first BDZ used for epilepsy and nowadays is a 
potent AED for the treatment of myoclonic seizures and subcortical myoclonus. Another 
important member of this family is Clorazepate (Traxene®), a prodrug for desmethyl 
diazepam and very rapidly produced as active metabolite. BDZs are partial agonist of the 
GABAA receptor which leads to increase the frequency of chloride ion channel opening and 
therefore to the inhibition of the synaptic transmissions across the CNS. Due to the 
development of tolerance and their sedative effect, BDZs are not appropriate for a long-term 
and adjunctive treatment of refractory epilepsy (Riss et al., 2008). 
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Scheme 9. Synthesis of clorazepate and clonazepam. 
Two general approaches have been reported for the access of 5-aryl-1-4-benzodiazepines. 
The first method, which is the condensation of 2-amino benzophenone derivatives with 
bromoacetyl bromide and ammonia or glycine alkyl esters, has been successfully applied to 
the synthesis of clonazepam (Vardanyan & Hruby, 2006). The alternative method includes 
an additional step which consists of the Grignard addition to benzonitriles to afford 
benzophenone imine intermediate before condensation with the corresponding 2-
aminomalonic ester derivate. Both approaches are high yielding and effective in the 
synthesis of benzodiazepines, therefore, the scope of their application has relied on the 
availability of starting materials. Thus, this second approach has been the method of choice 
for a straightforward and efficient access to clorazepate (Schmitt, 1970). 
www.intechopen.com
 
Drug Discovery in Epilepsy: A Synthetic Review 
 
11 
2.2.2 Gabapentin and pregabalin 
Despite being GABA analogues and having been designed as GABA agonists, both 
gabapentin (GBP, Neurontin®) and its more potent successor pregabalin (Lyrica®) have 
shown to be inactive at GABA receptors. Nevertheless, they are effective in several 
neurological and psychiatric conditions and they are conventionally used in the treatment of 
partial epilepsies. GBP´s mechanism of action was recently discovered (Eroglu et al., 2009) 
and demonstrates that by binding to the alpha2delta-1 receptor on neurons, GBP avoids 
synapse formation. The main advantage of these AEDs is that both are relatively well 
tolerated although they have some adverse effects, particularly in high doses, but these 
usually are relatively minor. Compared to GBP, pregabalin is more potent, absorbs faster 
and has greater bioavailability (Bryans & Wustrow, 1999). 
Two general approaches for the synthesis of geminally substituted aminomethyl acetic acid 
compounds are known (Johnson & Li, 2007): the transformation of geminal diacetic acids 
into suitable amido intermediates which rearrange to desired target (method A) and the 
reduction of saturated aminomethyl derivatives such as nitro-, cyano-, imino-, or oxime- 
containing geminal acetic acetates (method B). Method A constitutes the most 
straightforward procedure for the synthesis of GBP, which is efficiently accomplished in just 
3 steps in a 80% yield through the Hofmann rearrangement of 3,3-pentamethylene 
glutarimide intermediate (Ferrari et al., 2004). Pregabalin, for other hand, contains a chiral 
centre and requires an asymmetric approach for its synthesis. Typically, a racemic mixture 
of pregabalin or its intermediates is synthesized and then processes involving racemic chiral 
or enzymatic resolution are applied (method C), but the effective throughput of the process 
is reduced by 50%. Much effort has been focused on the development of enantioselective 
routes. The employment of chiral auxiliaries and ligands has proven to be effective but also 
unsuitable for the high cost of the reagents. However, asymmetric organocatalysis has 
emerged as a very efficient and sustainable alternative for the synthesis of enantiopure 
intermediates via conjugated addition of cyanide or nitromethane to the corresponding α,β-
unsaturated precursors (method D) (Bassas et al., 2009). 
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Scheme 10. General methods for the synthesis of gabapentin and pregabalin. 
2.2.3 Felbamate 
Felbamate (Felbatol®) was first marketed in the early 90s and reported as a potent 
anticonvulsant very effective against multiple seizure types (Pellock & Boggs, 1995). It is 
www.intechopen.com
  
Novel Treatment of Epilepsy 
 
12 
usually well tolerated but due to very serious side effects such as aplastic anemia and 
hepatic failure, its use is restricted to patients with severe refractory epilepsy or Lennox-
Gastaut syndrome. Felbamate´s mechanism of action is not known, but it has been reported 
as an allosteric antagonist at the NR2B subunit of the NMDA glutamate receptor and also as 
GABAA receptor agonist. 
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Scheme 11. General methods for the synthesis of felbamate. 
The synthesis of felbamate involves a two step procedure, for which during these years, 
different reaction conditions have been developed. The reduction of commercially available 
diethyl phenyl malonate to diol intermediate has been carried out with several reagents, 
among which sodium borohydride has performed the best results regarding effectiveness 
and handeling-purification (Walker et al., 1994). Its subsequent transformation into the 
corresponding carbamate has been studied using phosgene, chloroformate as well as 
cyanate derivates, but still urethane exchange constitutes the best method for preparing 
felbamate (Walker et al., 1994). 
2.2.4 Tiagabine 
Tiagabine (TBG, Gabitril®) is a GABA uptake inhibitor primarily used in combination with 
other AEDs for the treatment of partial seizures (Schachter, 1999). The precise mechanism of 
action is not known but it modulates the excitatory synaptic currents by retarding the 
neuronal reuptake of GABA into the presynaptic terminal, which leads to the maintenance 
of the extra cellular concentration of GABA. 
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Scheme 12. General methods for the synthesis of tiagabine. 
There is one general approach for the synthesis of TGB, which includes the Grignard 
addition of 2-metallo-3-methylthiofuran to different carbonyl electrophiles as common step 
(Andersen et al., 1993). When methylchloroformate is employed (method A), the resulting 
diarylketone can be transformed into the alkenyl precursor of TGB by reaction with 
cyclopropylmagnesium bromide and subsequent opening under acidic conditions or via 
Wittig olefination. However, the reaction of the Grignard with γ-butyrolactone or ethyl 3-
bromopropanoate (method B) has resulted as a much more straightforward and effective 
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method. Then, the synthesis of TGB is completed by the N-alkylation of the 4-bromo or 4-
tosylbutene intermediate with the corresponding protected cyclic amino acid. Recently, an 
alternative method (C) based on palladium catalyzed Sonogashira and Suzuki reactions for 
new carbon-carbon connections and CeCl3-NaI mediated diastereoselective hydroiodination 
of alkynes as key step has been published (Bartoli et al., 2010). Nevertheless, despite the 
synthetic importance of this newly developed methodology applied to the synthesis of TGB, 
still it lacks of practical and industrial extend. 
2.2.5 Levetiracetam and brivaracetam 
Levetiracetam (LEV, Keppra®) is a newly developed potent AED for the adjunctive therapy 
in the treatment of partial onset seizures in both adults and children. Even if its mechanism 
of action is not fully elucidated, it is known to target the synaptic vesicle protein 2A (SV2A) 
as well as high-voltage, N-type calcium channels. With a nearly ideal pharmacokinetics, 
LEV reveal a very good safety profile which makes it a very well tolerated AED and also 
efficient for different patient populations (Grosso et al., 2005). Brivaracetam (UCB 34714), 
the n-propyl derivate of LEV, possesses a ten-fold higher binding affinity for SV2A 
compared to LEV and it shows as a very promising new AED but still is under development 
(Malawka & Kulig, 2008). 
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Scheme 13. General methods for the synthesis of levetiracetam and brivaracetam. 
The main chemical disconnection of both LEV and brivaracetam occurs at the C-N-
pyrrolidinone bond, which can be accomplished by the alkylation of N-pyrrolidinone or N-
alkyl intermediate with an activated butyric acid derivative (method A) as well as by the 
construction of the pyrrolidinone ring from (s)-aminobutyramide or the methyl ester of (s)-
aminobutyric acid as nitrogen source (method B and C, respectively) (Kenda et al., 2004). 
Enantiomerically pure (s)-aminobutyric acid derivatives are readily available from L-
methionine and easier to obtain than the required butyric acid derivate in method A. Thus, 
by using method C, LEV has been successfully prepared in an overall 71% (Ates et al., 2003). 
However, the most efficient approach for the synthesis of brivaracetam consist of the 
palladium catalyzed diastereoselective reductive amination of aminobutyramide with a 
furan intermediate suitably prepared from butyric acid and glyoxalic acid (method 
B)(Surtees et al., 2005). 
2.2.6 Lacosamide 
The continuous search for new AEDs has lead to the discovery of a novel category of drugs 
labeled as Functionalized Amino Acids, among which lacosamide (LCM, Vimpat®) is the 
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first-in-class. LCM is effective for the adjunctive treatment of partial-onset seizures in adults 
and it has a novel mode of action: a "novel dual mechanism" consisting of selective 
enhancement of sodium channel slow inactivation and modulation of CRMP-2 activity 
(Chung, 2009). It is generally well tolerated but still presents regular side effects such as 
dizziness, nausea and vomiting. 
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Scheme 14. General methods for the synthesis of lacosamide. 
The synthesis of LCM is primarily based on the stepwise functionalization of L-serine, 
which starts in most of the cases with the protection of the free amine (method A). Then, 
after methylation of the hydroxyl group and amidation, the N-protecting group is removed 
and the amine acylated to afford LCM with high enantioselectivity and in good overall yield 
(Riedner & Dunne, 2008). Alternatively, and also starting from serine an elegant approach 
has been reported based on the selective ring opening of N-acetylazirine methylester 
(method C) (Morieux et al., 2008). For other hand, a new route beginning with ethyl 2,3-
dibromopropionate has been published recently in which additional chiral resolution step is 
necessary to obtained enantiomerically pure LCM (method B) (Bouvi et al., 2010). 
2.2.7 Topiramate and zonisamide 
Topiramate (Topamax®) is a highly effective anticonvulsant for the treatment of primary 
and secondary generalized tonic-clonic seizures as well as the Lennox Gastaut syndrome 
(Perucca, 1997). It differs from other AED in its structure, which is derived from D-fructose 
and also contains an unusual sulfamate functional group. Topiramate´s mechanism of action 
is not fully elucidated, but it shows inhibitory effect on voltage-dependent sodium channels 
and AMPA subtype glutamate receptor, and enhances some of GABAA receptors. 
Zonisamide (ZNS, Zonegran®, Excegran ®) is another sulfonamide containing AED, effective 
as adjunctive therapy in adults with partial onset seizures (Schulze-Bonhage, 2010). With an 
unknown mechanism of action, it is reported to block voltage-dependent sodium channels, 
which would lead to inhibit the spread of epileptiform activity, and the reduction of T-type 
calcium channel currents, or to inhibit the uptake of the inhibitory neurotransmitter GABA 
while enhancing the uptake of the excitatory neurotransmitter glutamate. ZNS is generally 
well-tolerated but also associated to various side effects such as drowsiness, loss of appetite, 
gastrointestinal problems and CNS toxicity. However, the rare occurrence of nephrolithiasis 
suggests a careful monitorization of patients. 
Sulfonamide containing AEDs are prepared via amidation of the corresponding sulfonyl 
derivative as last step. Thus, topiramate is readily available from D-fructose by 
condensation with acetone and transformation of the pendant hydroxyl group into a 
sulfonate derivative before amidation. Among the different reagents described for the 
sulfamoylation step, chlorosulfonyl isocyanate is the one providing better results regarding 
safety and effectiveness (Arvai eta al., 2006). For other hand, the synthesis of ZNS has been 
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accomplished following two general and complementary approaches: through a 1,2-
benzisoxazole-3-acetic acid intermediate derived from 4-hydroxycoumarin (method A) and 
the conversion of methyl salicylate into 1,2-benzoxathiin-4(3H)-one-2,2-dioxide, which is 
reacted with hydroxylamine to afford the corresponding sulfonyl 1,2-benzisoxazole in a 
later step (method B)(Arava et al., 2007). Despite the similarities between these two routes, 
the application of method A using chlorosulfonic acid as sulfonylating reagent has offered a 
higher-yielding (65% overall yield) and cost-effective process (Nageib et al., 2008) 
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Scheme 15. General methods for the synthesis of topiramate and zonisamide. 
2.2.8 Lamotrigine 
In addition to being approved in 1994 as an adjunctive treatment of partial seizures in adults, 
lamotrigine (LTG, Lamictal®) has shown since then a broad spectrum of antiepileptic activity 
(Malik et al., 2006). It may stabilize neuronal membranes by inhibition of voltage-sensitive 
sodium channel, but still the mechanism of action is unknown. Alternative to VPA, LTG 
shows a better side effect profile and also an important safety record in pregnancy, which 
makes it as the AED of choice in pregnant women with epilepsy (Sabers & Tomson, 2009). 
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Scheme 16. General methods for the synthesis of lamotrigine. 
The different methods for preparation of LTG can be classified according to the existing 
approaches for the formation of the triazine heterocyclic ring. The acid or base promoted 
intramolecular cyclization of aminoguanidine intermediates (method A) consists of the most 
studied and effective route so far, providing desired LTG product in moderate yield (52%) 
(Dalmasses Barjoan & Bessa Bellmunt, 2004). Alternatively, the synthesis of LTG has been 
also accomplished by using tetrazolamine instead of aminoguanidine (method B)(Ulomskii 
et al., 2005) or by the direct Suzuki coupling of a preformed diamino triazine halide with the 
corresponding boronic acid (method C) (Titirmare, 2007). But despite the potential 
applicability of these two approaches, the preparation of required intermediates as well as 
the poor reaction yields obtained limits considerably their scope.  
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2.3 New generation AEDs 
Despite the continuous research and advances in the field, none of the currently available 
treatments for epilepsy accomplishes satisfactory control of seizures without causing 
important side effects. Therefore, ongoing studies towards the development of new AEDs 
regarding efficiency, tolerability and safety have been carried out and have lead to a new 
generation of AEDs, most of which have already undergone preclinical and clinical studies 
(Bialer et al., 2010; Stephen & Brodie, 2011). Some of these new candidates are optimized 
analogues of known AEDs, such as eslicarbazepine acetate (see section 2.11 for more details) 
or brivaracetam, but most of them are being developed with novel mechanisms and clinical 
characteristics compared with previous AEDs: Perampanel was designed as an AMPA-type 
glutamate receptor antagonist, retigabine modulates neuronal KV7.2–7.5 voltage-activated 
K+ channels while 2-deoxy-D-glucose acts on the NRSF-CtBP–dependent metabolic 
regulation of chromatin structure.  
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Scheme 17. Chemical structures of the new generation of AEDs. 
Given the heterogeneity of their functions, they show big differences on their chemical 
structures as well as their occurrence. Thus, Huperzine A is a natural sesquiterpene alkaloid 
and both 2-deoxy-D-glucose and ganaxolone are analogues and therefore easily available 
from D-glucose and progesterone respectively. Most of the new AEDs, nevertheless, are 
synthetic small molecules whose preparation processes are not yet reported or even with 
unknown structures as for ICA-105665, NAX 5055 or YKP3089 candidates. 
3. Conclusion 
To sum up, there is a broad spectrum of compounds active against several seizure types. In 
addition to the synthetic approaches patented by the pharmaceutical companies that 
discovered or marketed them, an acceptable (and in some cases overwhelming) number of 
preparation strategies to these AEDs have been reported, thus overcoming in some cases 
problems (low overall yields, long sequences, harsh conditions, etc.) encountered in the 
initial protocols. Since a variety of structural motifs (dibenzoazepines, imidazodiones, 
benzodiazepines, piperidines, triazines, isoxazoles, pyrrolidinones, etc.) has proved activity 
in antiepileptic therapy, a complete arsenal of synthetic tools has been required for their 
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preparation. It becomes clear to the reader that a valuable evolution from classical 
transformations to modern (stereoselective, catalytic, more sustainable) procedures has 
occurred also in this field. However, only in a limited number of cases can be found whole 
approaches with an extensive scope, that is, applicable to the preparation of a reasonably 
diverse series of structural analogs that could provide more effective drugs and/or reduced 
side-effects. One of the main features of the aforementioned evolution in the future will be 
probably related to filling the latter gap.  
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